Berlin – A comprehensive new analysis of glucagon-like peptide-1 (GLP-1) receptor agonists, medications initially developed to treat type 2 diabetes, reveals significant benefits for both cardiovascular health and, crucially, kidney function. The findings, published in The Lancet Diabetes & Endocrinology, suggest these drugs could play a pivotal role in managing chronic kidney disease (CKD) and … Read more
Source link